MedPal AI (LSE:MPAL) is demonstrating the growth potential of its digital healthcare platform, with its New Health business rapidly expanding its customer base in the UK GLP-1 market while increasing repeat business and investing in the infrastructure needed to support further growth.
Since launching in July and beginning marketing activity in August, New Health has climbed from 3,048th to 29th in Eli Lilly’s Mounjaro supplier rankings in just three months. The platform has attracted more than 42,500 customers, highlighting the strong demand for its competitively priced digital healthcare services.
For MedPal AI, the opportunity extends beyond acquiring customers. The company is focused on combining technology, operational efficiency and customer retention to build a scalable business capable of generating recurring revenue across multiple healthcare channels.
Technology and competitive pricing drive customer acquisition
MedPal AI’s CEO, Jason Drummond, attributes New Health’s rapid progress to the combination of an efficient service, competitive pricing and the use of artificial intelligence and robotics to reduce operating costs.
By leveraging these technologies, the company aims to offer customers strong value while maintaining attractive returns on individual orders. This approach has helped New Health establish a competitive position in the growing UK market for GLP-1 treatments, including Mounjaro.
The rapid rise through Eli Lilly’s supplier rankings provides a clear indication of the platform’s early commercial traction. With tens of thousands of customers already signed up, New Health has established a substantial base from which to develop its next phase of growth.
Repeat business strengthens the revenue model
While customer acquisition has been a major driver of New Health’s early success, MedPal AI is also reporting encouraging progress in customer retention.
According to Drummond, repeat orders now account for more than 30% of New Health’s revenue, up from approximately 20% in the previous month. This growing contribution from returning customers is an important development as the company works to establish a more sustainable and predictable revenue model.
Drummond highlighted the importance of retaining customers across the business, explaining that attracting large numbers of new users is only part of the equation. Converting those customers into repeat purchasers is central to building long-term value.
This focus on repeat revenue extends across MedPal AI’s broader healthcare operations, including NHS prescribing, care home services and New Health’s GLP-1 offering. Together, these activities provide the company with opportunities to develop customer relationships and generate ongoing demand across different areas of digital healthcare.
Infrastructure supports the next stage of expansion
Supporting rapid growth requires operational capacity as well as customer demand. MedPal AI has invested millions of pounds in its Sarus Court distribution hub in the north of England, providing infrastructure designed to accommodate the growing volume of orders.
The investment reflects the company’s focus on building the operational foundations required to support its expanding customer base. As New Health continues to develop, fulfilment capacity and efficiency will remain important factors in delivering a consistent service while managing costs.
The combination of an established distribution facility, technology-led operations and an increasing proportion of repeat revenue gives MedPal AI a platform from which to pursue further growth.
Building a scalable digital healthcare business
New Health’s progress illustrates MedPal AI’s wider strategy of applying technology and operational efficiency to healthcare services with recurring customer demand.
The business has moved quickly from launch to a position among the leading Mounjaro suppliers by ranking, while the increase in repeat revenue suggests that its proposition is gaining traction beyond initial customer sign-ups.
For MedPal AI, the next phase will centre on maintaining customer growth, encouraging repeat orders and ensuring its infrastructure can support expanding demand. The company’s broader healthcare activities also provide additional avenues for developing recurring revenues.
With more than 42,500 New Health customers, repeat business contributing over 30% of revenue and significant investment already made in distribution capacity, MedPal AI is building the foundations for its next stage of development.
The challenge now is to sustain that momentum, converting early commercial success into a growing, efficient and repeat-revenue-led digital healthcare business.
Leave a Reply